SCHEMBL21418353

SCHEMBL21418353

Cc1cc(C)c(CNCc2cc(-c3ccc(N4CCNCC4)nc3)nc3c2cnn3C(C)C)c(=O)[nH]1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 13/20 0.78
▸ EZH1 Q92800 4/20 0.55
▸ EED O75530 2/20 0.55
▸ RBBP4 Q09028 2/20 0.55
▸ SUZ12 Q15022 2/20 0.55
▸ RBBP7 Q16576 2/20 0.55
▸ AEBP2 Q6ZN18 1/20 0.55
▸ HDAC6 Q9UBN7 7/20 0.51
▸ HDAC1 Q13547 5/20 0.51
▸ HDAC4 P56524 1/20 0.51
▸ HDAC7 Q8WUI4 1/20 0.51
▸ HDAC2 Q92769 1/20 0.51
▸ HDAC10 Q969S8 1/20 0.51
▸ HDAC11 Q96DB2 1/20 0.51
▸ HDAC8 Q9BY41 1/20 0.51
▸ HDAC9 Q9UKV0 1/20 0.51
▸ HDAC5 Q9UQL6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21418352 0.93 EZH2 (0.68) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL21418348 0.91 EZH2 (0.64) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL12498771 0.87 EZH2 (1.00) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL20170308 0.85 EZH2 (0.85) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL21418341 0.84 EZH2 (0.56) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL10255922 0.81 EZH2 (0.88) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL17734355 0.81 EZH2 (0.89) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL1695598 0.80 EZH2 (0.87) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL19391309 0.79 EZH2 (0.61) EZH2EZH1
SCHEMBL12684278 0.79 EZH2 (0.84) EZH2EZH1EEDRBBP4SUZ12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190300502-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2019-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300502-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 EZH2 1355/4885EZH1 2661/4885EED 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback